by In2Pharma | Jul 20, 2026 | News
Belgium New measures concerning pregabalin and gabapentin entered into force on July 19, 2026. In the meantime, an erratum has been published in the Belgian Official Gazette. The correction was necessary because the last line of the table included in the new Annex IVC...
by In2Pharma | Jul 16, 2026 | News
Belgium The Animal Health Group of pharma.be has released an updated Code of Ethics, replacing the previous 2017 version to reflect the latest European veterinary medicines legislation and current industry practices. The revised Code strengthens the sector’s...
by In2Pharma | Jul 13, 2026 | News
Europe The CMDh has agreed to remove the requirement to submit a cover letter for Type IA and Type IAin variation applications. This change took effect on 1 July 2026. To reflect this update, several guidance documents have been revised, including: Requirements on...
by In2Pharma | Jul 13, 2026 | News
Luxembourg On 10 June 2026, the General Assembly of Innovative Medicines for Luxembourg (IML) approved a revised version of the IML Code of Ethics. The updated code introduces several targeted changes, including new provisions on complaints, a dedicated patient...
by In2Pharma | Jun 4, 2026 | News
Belgium The Belgian Health Authorities (FAMHP) have recently published a guidance document on the interpretation of Article 10 of the Law of 25 March 1964 regarding premiums and benefits. This document aims to further clarify the legal framework governing the granting...
